Ascelia Pharma
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Ascelia Pharma Announces Management Changes to Support Future Growth
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced changes to its executive leadership team. These changes are designed to strengthen the company’s operational capabilities and position it for its next phase of growth.
Ascelia Pharma has recruited Anton Hansson as Chief Financial Officer (CFO) who will join the company around late January 2026. Anton Hansson comes with a background in corporate finance, most recently from KPMG. The CFO role has until now been held in a dual capacity by the company’s Deputy CEO and Chief Commercial Officer. In addition, Jennie Wilborgsson, currently Vice President of Clinical Development, has been promoted to Chief Operating Officer (COO). The executive leadership team now consists of five members: CEO, Deputy CEO and CCO, CSO, COO and CFO, forming a streamlined and focused management structure aligned with the company’s strategic priorities.
“While we continue to focus on the important milestones ahead for Orviglance, these changes mark an important step in preparing Ascelia Pharma for the next chapter in our growth journey,” said Magnus Corfitzen, Chief Executive Officer.
| Datum | 2025-11-03, kl 09:55 |
| Källa | MFN |